LLY
Eli Lilly and Company
LLY has the edge over RMD overall, supported by stronger fundamentals and stronger modeled upside.
RMD
ResMed Inc.
RMD has slightly lower modeled downside risk, despite its lower overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
RMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
RMD's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
RMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $239 | — |
| Current | 22x | $239 | — |
| Cheap | 26x | $280 | +17% |
| Fair | 37x | $410 | +71% |
| Expensive | 54x | $595 | +149% |
Historical ranges are pointers, not guarantees.
RMD has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over RMD on the outlook, with more favorable revenue expectations.
RMD Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect RMD's earnings to grow and its profitability to improve, with its revenue holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over RMD on earnings, with stronger typical year-over-year growth.
RMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $12.30 | +12% |
| Q3 2026 | $10.98 | +12% |
| Q2 2026 | $10.43 | +9.7% |
| Q1 2026 | $10.37 | +17% |
| Q4 2025 | $10.11 | +20% |
| Q3 2025 | $9.77 | +30% |
| Q2 2025 | $9.51 | +37% |
| Q1 2025 | $8.90 | +37% |
| Q4 2024 | $8.46 | +40% |
RMD's earnings per share have climbed steadily: $10.98 over the past year, up 12% from the year before, and higher year over year for 19 quarters in a row.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over RMD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over RMD on profitability, with a higher operating margin.
RMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +5.9% |
| Q2 2026 | $1.5B | +8.6% |
| Q1 2026 | $1.4B | +11% |
| Q4 2025 | $1.4B | +11% |
| Q3 2025 | $1.3B | +9.1% |
| Q2 2025 | $1.3B | +10% |
| Q1 2025 | $1.3B | +7.9% |
| Q4 2024 | $1.3B | +10% |
RMD's revenue has grown year over year for 22 quarters in a row: $1.4B last quarter, up 5.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.4 points |
| Q2 2026 | 31% | -3.1 points |
| Q1 2026 | 35% | +1.9 points |
| Q4 2025 | 35% | +2 points |
| Q3 2025 | 33% | +1.8 points |
| Q2 2025 | 34% | +2.5 points |
| Q1 2025 | 33% | +1.7 points |
| Q4 2024 | 33% | +8.9 points |
RMD's operating margin was 32% last quarter, down 1.4 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over RMD on cash flow, with more consistent year-over-year improvement.
RMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $373.7M | -9.8% |
| Q2 2026 | $403.5M | -21% |
| Q1 2026 | $520.5M | -6.7% |
| Q4 2025 | $311.2M | +8.1% |
| Q3 2025 | $414.4M | +35% |
| Q2 2025 | $508.2M | +22% |
| Q1 2025 | $557.9M | +46% |
| Q4 2024 | $288M | +15% |
RMD generated $1.6B in free cash flow over the past year, down 9% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
RMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.8% | -2.6M shares |
| 1 year | -2.4% | -3.5M shares |
| 3 years | -2.8% | -4.1M shares |
| 5 years | -2.3% | -3.4M shares |
| Available history | -1.5% | -2.2M shares |
RMD has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $936.4M |
| Q2 2026 | $200M |
| Q1 2026 | $175M |
| Q4 2025 | $175M |
| Q3 2025 | $150M |
| Q2 2025 | $100M |
| Q1 2025 | $75M |
| Q4 2024 | $75M |
RMD spent $1.5B buying back its own shares over the past year, about four times what it spent the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
RMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.5x | Net Cash |
| Q4 2025 | -0.4x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.3x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | 0.1x | Very low |
RMD has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
RMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.7 | Neutral |
| Stochastic | 60.7 | Neutral |
RMD's weekly RSI is 56 (neutral) and its Stochastic is 61 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
RMD PE vs Healthcare Sector
| Metric | RMD | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 26x | 16% below |
| PE % | 6 | 29 | 23 pts below |
RMD has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
RMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $233.4 | 2.4% above |
| 20 week MA | $223.3 | 7% above |
| 50 week MA | $227.8 | 4.8% above |
| 100 week MA | $238.7 | 0.1% above |
| 200 week MA | $220.5 | 8.3% above |
RMD is in an uptrend: it's above all five of its weekly moving averages, and 8.3% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over RMD on returns for 2026, with the stronger performance.
RMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $156.2 | $212.4 | +36% |
| 2021 | $212.4 | $258.8 | +22% |
| 2022 | $258.8 | $208.3 | -20% |
| 2023 | $208.3 | $172.0 | -17% |
| 2024 | $172.0 | $233.2 | +36% |
| 2025 | $233.2 | $244.8 | +5% |
| 2026 YTD | $244.8 | $238.9 | -2.4% |
RMD has finished higher in four of the last six years. It's down 2.4% so far in 2026.